PriceTargets.com logo

NASDAQ:SYBX - Synlogic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 181.17 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.09 As of 01/25/2021 01:00 AM ET
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Synlogic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.50
▲ +181.17% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $11.50, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 181.17% upside from the last price of $4.09.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Synlogic. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Chardan CapitalBoost Price TargetBuy$5.00 ➝ $10.00High
i
9/18/2020Chardan CapitalReiterated RatingBuy$5.00Medium
i
8/10/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2020HC WainwrightReiterated RatingBuy$13.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2020OppenheimerReiterated RatingHoldMedium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/23/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/12/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/13/2020HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/11/2019HC WainwrightReiterated RatingBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/13/2019Piper Jaffray CompaniesReiterated RatingOverweight$10.00 ➝ $7.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/19/2019Chardan CapitalReiterated RatingBuyHigh
i
Rating by G. Amusa at Chardan Capital
9/9/2019HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/4/2019Piper Jaffray CompaniesSet Price TargetBuy$10.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/21/2019HC WainwrightLower Price TargetBuy$22.00 ➝ $13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/21/2019CitigroupDowngradeBuy ➝ Sell$20.00 ➝ $2.00High
i
8/20/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
8/20/2019Piper Jaffray CompaniesReiterated RatingOverweight$10.00 ➝ $20.00High
i
8/12/2019HC WainwrightReiterated RatingBuy$22.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/9/2019WedbushReiterated RatingOutperform$20.00Low
i
7/16/2019HC WainwrightBoost Price TargetBuy$20.00 ➝ $22.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/15/2019Chardan CapitalSet Price TargetBuy$25.00High
i
Rating by Taylor Feehley at Chardan Capital
7/15/2019Piper Jaffray CompaniesBoost Price TargetOverweight$16.00 ➝ $20.00Low
i
6/24/2019HC WainwrightReiterated RatingBuy$20.00Low
i
6/12/2019WedbushReiterated RatingOutperform$20.00High
i
6/12/2019Piper Jaffray CompaniesBoost Price TargetOverweight$15.00 ➝ $16.00High
i
4/30/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$18.00High
i
4/12/2019Chardan CapitalSet Price TargetBuy$20.00Medium
i
Rating by Taylor Feehley at Chardan Capital
3/12/2019Chardan CapitalReiterated RatingBuy$20.00High
i
Rating by T. Feehley at Chardan Capital
2/12/2019BTIG ResearchInitiated CoverageBuy$22.00 ➝ $22.00High
i
12/13/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$20.00Medium
i
Rating by T. Feehley at Chardan Capital
12/10/2018HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/13/2018HC WainwrightReiterated RatingBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/12/2018OppenheimerSet Price TargetBuy$18.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/9/2018HC WainwrightSet Price TargetBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/7/2018WedbushReiterated RatingOutperformLow
i
9/5/2018CitigroupBoost Price TargetBuy$26.00High
i
8/24/2018CitigroupUpgradeNeutral ➝ BuyHigh
i
8/9/2018HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
6/29/2018OppenheimerInitiated CoverageOutperform$18.00High
i
6/11/2018HC WainwrightReiterated RatingBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2018HC WainwrightSet Price TargetBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/11/2018HC WainwrightSet Price TargetBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/17/2018HC WainwrightReiterated RatingBuy$20.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/9/2018Piper Jaffray CompaniesReiterated RatingBuy$15.00Low
i
4/4/2018HC WainwrightSet Price TargetBuy$20.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/19/2018HC WainwrightInitiated CoverageBuy ➝ Buy$20.00Low
i
Rating by R. Selvaraju at HC Wainwright
1/29/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$16.00High
i
11/27/2017WedbushInitiated CoverageOutperform$20.00Medium
i
Rating by D. Nierengarten at Wedbush
9/19/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
4/13/2017Cantor FitzgeraldReiterated RatingHold$14.00Low
i
11/15/2016HC WainwrightReiterated RatingHoldN/A
i
Rating by shaunak deepak at HC Wainwright
9/23/2016HC WainwrightDowngradeBuy ➝ Neutral$42.00 ➝ $14.00N/A
i
Rating by S. Deepak at HC Wainwright
9/22/2016CitigroupLower Price TargetNeutral$31.50 ➝ $14.00N/A
i
9/21/2016SVB LeerinkReiterated RatingHold ➝ Neutral$28.00 ➝ $10.50N/A
i
9/21/2016OppenheimerDowngradeOutperform ➝ Market PerformN/A
i
9/21/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$98.00 ➝ $14.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/12/2016HC WainwrightInitiated CoverageBuy$6.00N/A
i
Rating by S. Deepak at HC Wainwright
8/16/2016OppenheimerBoost Price TargetOutperform$49.00 ➝ $91.00N/A
i
8/16/2016CitigroupDowngradeBuy ➝ Neutral$49.00 ➝ $31.50N/A
i
8/15/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$70.00 ➝ $28.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
5/13/2016Cantor FitzgeraldReiterated RatingBuy$98.00N/A
i
3/30/2016SVB LeerinkLower Price TargetOutperform$98.00 ➝ $70.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
2/19/2016CitigroupLower Price Target$63.00 ➝ $49.00N/A
i
(Data available from 1/26/2016 forward)
Synlogic logo
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.09
$3.98
$4.14

50 Day Range

MA: $2.62
$2.11
$4.27

52 Week Range

Now: $4.09
$1.35
$4.30

Volume

489,611 shs

Average Volume

3,262,617 shs

Market Capitalization

$142.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Synlogic?

The following Wall Street sell-side analysts have issued research reports on Synlogic in the last year: Chardan Capital, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.

What is the current price target for Synlogic?

2 Wall Street analysts have set twelve-month price targets for Synlogic in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 181.2%. HC Wainwright has the highest price target set, predicting SYBX will reach $13.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $10.00 for Synlogic in the next year.

What is the current consensus analyst rating for Synlogic?

Synlogic currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYBX will outperform the market and that investors should add to their positions of Synlogic.

What other companies compete with Synlogic?

Other companies that are similar to Synlogic include Atreca, Chimerix, Xenon Pharmaceuticals, Altimmune, Prothena, Geron, IDEAYA Biosciences, Akebia Therapeutics, Pandion Therapeutics, SIGA Technologies, RAPT Therapeutics, resTORbio, XBiotech, Viking Therapeutics and Spero Therapeutics.

How do I contact Synlogic's investor relations team?

Synlogic's physical mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company's listed phone number is 617-401-9975 and its investor relations email address is [email protected] The official website for Synlogic is www.synlogictx.com.